Guidance
← Отчётные звонки
01
02
03
04 05 06
Тон
AI
Капзатраты
A1 A2
TMO
FY2025 Q4
Улучшается
Отчётный звонок Thermo Fisher Scientific Inc
Вывод Buzzberg
2026 guidance assumes 3-4% organic growth and 6-8% EPS growth
Thermo Fisher reported a strong Q4 2025 with 7% revenue growth and 8% EPS growth, beating its own guidance. Management guided 2026 to 4-6% reported revenue growth and 6-8% EPS growth, assuming stable end markets and continued share gains. Key cross-company signals included a Bayer companion diagnostic win, partnerships with OpenAI and NVIDIA, and acquisitions from Solventum and Sanofi, while highlighting tight sterile fill-finish capacity and strong bioproduction demand. Q4 revenue $12.21B (+7% YoY), adjusted EPS $6.57 (+8%), both ahead of guidance.
Вывод Buzzberg 2026 guidance assumes 3-4% organic growth and 6-8% EPS growth Thermo Fisher reported a strong Q4 2025 with 7% revenue growth and 8% EPS growth, beating its own guidance. Management guided 2026 to 4-6% reported revenue growth and 6-8% EPS growth, assuming stable end markets and continued share gains. Key cross-company signals included a Bayer companion diagnostic win, partnerships with OpenAI and NVIDIA, and acquisitions from Solventum and Sanofi, while highlighting tight sterile fill-finish capacity and strong bioproduction demand. Q4 revenue $12.21B (+7% YoY), adjusted EPS $6.57 (+8%), both ahead of guidance. Читать полный анализСвернуть анализ
Thermo Fisher reported a strong Q4 2025 with 7% revenue growth and 8% EPS growth, beating its own guidance. Management guided 2026 to 4-6% reported revenue growth and 6-8% EPS growth, assuming stable end markets and continued share gains. Key cross-company signals included a Bayer companion diagnostic win, partnerships with OpenAI and NVIDIA, and acquisitions from Solventum and Sanofi, while highlighting tight sterile fill-finish capacity and strong bioproduction demand. Q4 revenue $12.21B (+7% YoY), adjusted EPS $6.57 (+8%), both ahead of guidance.
- 2026 guidance: revenue $46.3-47.2B (4-6% reported), adjusted EPS $24.22-24.80 (6-8% growth), organic growth 3-4%.
- Biopharma end-market grew mid-single digits full-year; bioproduction and clinical research drove results.
- Bayer companion diagnostic approval and collaborations with OpenAI, NVIDIA highlight innovation partnerships.
Выручка$12.215B+10% к/к
EPS$6.57+13% к/к
Валовая маржа37.95%Факт
Операционная маржа18.85%Факт
6 подтверждённых тезисов
Что важно сейчас
Самые значимые изменения по итогам звонка.
M&A
Clario acquisition expected to close mid-2026, accretive to EPS
Demand
Biotech funding improving, but spending lags by six months
Показать ещё 3 тезиса
Guidance
Q1 2026 organic growth expected a few points below full year
Margins
2025 tariffs and FX headwind over 100 bps to margins
Innovation
R&D investments focused on high-impact innovation
Отчётный период
Фактические результаты
| Показатель | Факт | Изменение |
|---|---|---|
| Выручка | $12.215B | +10% к/к |
| EPS | $6.57 | +13% к/к |
| Валовая маржа | 37.95% | Факт |
| Операционная маржа | 18.85% | Факт |
| Свободный денежный поток | $2.992B | Факт |
| Капзатраты | $0.465B | Факт |
Прогнозные данные
Прогноз компании
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| EPS | FY2026 | $24.22–$24.80 | $24.51 | Начат |
| Свободный денежный поток | FY2026 | $6.8B–$7.3B | $7.05B | Начат |
| Выручка | FY2026 | $46.3B–$47.2B | $46.75B | Начат |
AI, капзатраты и спрос
Оценка менеджмента
Confident
Management expressed confidence in execution and growth strategy, noted strong customer sentiment and innovation momentum, and reaffirmed guidance.
Оценка AI от менеджмента
Management is integrating AI into operations and products, with a strategic collaboration with OpenAI to embed AI capabilities and improve productivity, and an NVIDIA collaboration for analytical instruments.
Инвестиции и мощности
Net capital expenditures are expected to increase to $1.8-2.0 billion in 2026, driven by investments in U.S. manufacturing.
все упомянутые компании ниже: 7
Компаниис момента звонка
Клиенты
Клиенты
Mark Casper
Thermo Fisher's Oncomind DX test was FDA-approved as a companion diagnostic for Bayer's therapy, strengthening Bayer's targeted lung cancer treatment and driving demand for Thermo Fisher's NGS diagnostics.
Доказательства
“this technology received another FDA approval, this time as a companion diagnostic for Bayer's new therapy targeted for certain patients with non-small cell lung cancer.”
Партнёры
OPENAI
Партнёры
Mark Casper
Thermo Fisher is partnering with OpenAI to embed AI across its products and operations, potentially accelerating drug development and improving productivity—a positive signal for OpenAI's enterprise adoption in life sciences.
Доказательства
“announced a strategic collaboration with OpenAI aimed at increasing our use of artificial intelligence at the company.”
Партнёры
Mark Casper
Thermo Fisher's collaboration with NVIDIA leverages AI in analytical instruments and microscopy, positioning NVIDIA's chips in high-end scientific computing applications.
Доказательства
“announced an interesting collaboration with NVIDIA at the beginning of the year.”
Цепочка поставок
Цепочка поставок
Mark Casper
Thermo Fisher acquired Solventum's filtration and separation business to extend bioproduction capabilities; Solventum divests a non-core unit for cash.
Доказательства
“completed the acquisition of our filtration and separation business from Solventum.”
Цепочка поставок
Mark Casper
Thermo Fisher acquires a sterile fill-finish plant from Sanofi, boosting its CDMO capacity; Sanofi monetizes a site while outsourcing fill-finish capacity.
Доказательства
“expanded our U.S. drug product manufacturing footprint through the acquisition of Sanofi's state-of-the-art sterile fill finish site in New Jersey.”
Цепочка поставок
Mark Casper
Thermo Fisher's bioproduction business delivered 'excellent growth' for another quarter, signaling sustained demand for single-use technologies and cell culture media. — Ongoing bioprocessing demand suggests peer companies in biologics manufacturing supplies (Danaher, Sartorius) may also see tailwinds.
Доказательства
“Performance in the quarter was led by continued strong growth in our bioproduction business”
Внешние сигналы
Альфа цепочки поставок · 2с момента звонка
Sterile fill-finish capacity is tight, driving Thermo Fisher to acquire Sanofi's site and win reshoring contracts, indicating supply constraints for drug manufacturers.
Доказательства
“sterile full finish has been the area where there is heightened demand relative to industry capacity”
Thermo Fisher's bioproduction business delivered 'excellent growth' for another quarter, signaling sustained demand for single-use technologies and cell culture media.
Методология и полнота
Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 7. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.